The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.
News Archive
Showing 35 results
September 2022
-
Media ReleaseNovartis and the pan-Canadian Pharmaceutical Alliance (pCPA) conclude negotiations for Luxturna®, a gene therapy for previously untreatable inherited vision loss¹Luxturna® (voretigene neparvovec) is a one-time gene therapy that provides healthy copies of the RPE65 gene for retinal cells that are lacking the normally functioning gene1 Dorval, QC, September 20…
-
Media ReleaseHealth Canada approves PLUVICTO™ as first targeted radioligand therapy for progressive PSMA positive metastatic castration-resistant prostate cancerNovel mechanism of action of PLUVICTO™ binds to target PSMA-positive cancer cells, delivering radiation treatment directly to those cells and nearby cells1 Prostate cancer is the most diagnosed…
June 2022
-
Media ReleaseNovartis Pro Portal reimagines knowledge exchange in patient care, with seamless collaboration between the pharmaceutical industry and physiciansThe product of over 120 consultations with health care practitioners, the Novartis Pro Portal is a one-stop digital hub developed to provide tailored, real-time support in daily practice. Dorval, QC…
-
Media ReleaseHealth Canada approves PrTabrecta®: Targeted cancer therapy for locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterationsNewest treatment for lung cancer reinforces Novartis commitment to developing innovative therapies that improve outcomes for Canadians affected by advanced lung cancer Dorval, Quebec, June 8, 2022 –…
October 2021
-
Media ReleaseNovartis launches Not Another Minute to educate Canadians and take action to bend the curve of cardiovascular disease (CVD)In Canada, cardiovascular disease accounted for more than 52,000 deaths annually between 2015 and 20191 Almost 80% of deaths from cardiovascular disease are preventable2. Novartis is joining forces…
-
Media ReleaseNovartis applauds Quebec, the first province to list Zolgensma® for the treatment of pediatric patients with spinal muscular atrophy (SMA)Public reimbursement is effective October 20th and will apply for children with SMA following the recommendation from the Institut national d'excellence en santé et services sociaux Zolgensma is the…
-
Media ReleaseNew campaign highlights urgent need for action to address the growing crisis of preventable vision loss and blindnessThis World Sight Day, Fighting Blindness Canada and the Canadian Council of the Blind have partnered with Novartis Canada to launch “All Eyes on You”, a campaign urging Canadians to lend their voices…
-
Media ReleaseNovartis and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for Zolgensma® for the treatment of pediatric patients with spinal muscular atrophy (SMA)Dorval, Quebec, October 13, 2021 — Novartis Pharmaceuticals Canada Inc. today announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent…